Two phase III RCTs (ADJUVANT and IMPACT) that reported their final OS analysis at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021 showed that adjuvant gefitinib appeared to prevent early relapse in patients with completely resected stage II-III EGFR-mutant NSCLC but did not significantly prolong OS in these patients [13, 14]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.